I think these three attributes will help Array do well over the long haul. Stock prices have dropped 40% off their 52 week high when Amgen pulled out of its contract, but the majority of its profit potential is still intact with the current pipeline. The phase III studies are still in the recruiting phases, so it will be some time before Array will be able to seek FDA approval and generate sales. But their strength is in clinical asset generation, and I am confident that their kinase screening methodology with (will) produce revenue generating partnerships. The release of binimetinib from its contract or additional preclinical contracts or the success of two clinical milestones coming up in August could lead to a jump in stock price. That said, it's important to remember that this is a clinical stage biotech that's going through a lot of cash -- Array is sitting on about $110 million, but burned through $64 million over the trailing 12 months. So while the stock may have some exciting opportunities ahead, it's still speculative and very risky.
So I'll tell ya what I want, really really want. I want I want I want, ARRY said AHHHH.
JULY good month...wish someone would have told us on June 28th when it was at 4.25/share, LOL
WOW, my calculator says that dude has 12.9 mil shares, now that's a player. No wonder the A/D line was showing big-time accumulation..
Sentiment: Strong Buy
Maybe, I just noticed irwd the other day, funds own 118%, short interest down 5 million, sales of their one drug growing q/q through various partners, mainly Forest labs.
LINZESS net product sales, as reported by Forest Laboratories, Inc., were $51.0 million in the fourth quarter of 2013, an increase of approximately 48% quarter over quarter, and $118.8 million for the year ended December 31, 2013.
• LINZESS net product sales, as reported by Forest Laboratories, Inc., were $60.8 million in the first quarter of 2014, an increase of approximately 19% quarter over quarter.
So at 60m Q1 = 240 annual, a double from 2013 sales of 118.
Their pipeline appears smallish and much around this one drug, but looks like they have a global plan for the drug with partners other than forest, maybe double the 240, to 480M if global plan works. It is worth following, but I am not in a position to jump in at this point.
You're right about the IRWD chart, but I don't like the way the indicators look. The MACDHist is flat, and the Chaikin Oscillator doesn't look healthy... The RSI is bumping up against 70, so the shorts will be getting more involved.
I missed the move in AGEN, it's really taking off.
I can't speak to all the technical, but you want a nice chart look at ironwood pharma, irwd. Not sure if this heads to all time highs, or is ready to top, but the chart is awesome.
It's too bad yoohoo doesn't doesn't roll-up worthless trash like you.
Yeah, him. Treated the company as his personal piggy bank, screwed up the dosing for 907, wasted time trying Debio 0932 as an IV drug and read up on the sham businesses of the one board member.
Is that the guy that just stepped down??
On June 2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of Curis, Inc. (the "Company"). Mr. Passeri will continue to serve as a Class II director of the Company. On June 2, 2014, the board of directors (the "Board") of the Company elected Mr. Passeri Vice Chairman of the Board.
Nice pipeline coming on CCXI:
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohns disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The companys drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997
Not until you mentioned it. That fund that upped it's stake in arry, I looked over a few of their holdings, it is a bio only fund. A new buy was ccxi, up as arry past two days, range 4.57-14.75, currently 5.97, it is sort of interesting too.